Congress Scientific Watch

From 2023 ASCO GI Cancers Symposium:
The SUNLIGHT trial shows a significant improvement in the overall survival of patients with refractory metastatic colorectal cancer with the addition of bevacizumab to trifluridine and tipiracil  

From 2023 ASCO GI Cancers Symposium:
Adding bevacizumab to atezolizumab and chemotherapy does not significantly improve the outcomes of people with treatment-naïve advanced biliary tract cancer

From 2023 ASCO GI Cancers Symposium:
Adding stereotactic body radiation therapy to sorafenib significantly improves survival outcomes for patients with locally advanced hepatocellular carcinoma unsuitable for surgery, ablation or transarterial embolisation

From 2023 ASCO GI Cancers Symposium:
Adding zolbetuximab to chemotherapy extends overall survival for previously untreated patients with unresectable locally advanced or metastatic gastric and gastro-oesophageal junction adenocarcinoma

From 2023 ASCO GI Cancers Symposium:
Phase III trial findings point to a significant overall survival improvement with regorafenib versus placebo for treatment-refractory locally advanced or metastatic gastric or oesophagogastric junction cancer

From 64th ASH Annual Meeting & Exposition:
The phase III ALPINE trial demonstrates a progression-free survival advantage for zanubrutinib versus ibrutinib among patients with relapsed or refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma

From 64^th ASH Annual Meeting & Exposition:
Individuals with primary central nervous system lymphoma have better survival when given consolidation high-dose chemotherapy and autologous stem cell transplantation rather than non-myeloablative chemoimmunotherapy

From 64th ASH Annual Meeting and Exposition:
A study of patients aged up to 65 years with treatment-naïve mantle cell lymphoma supports the use of ibrutinib alongside chemotherapy and autologous stem cell transplantation

From San Antonio Breast Cancer Symposium 2022:
Women with early-stage, hormone receptor-positive breast cancer can be reassured that interrupting endocrine therapy to attempt pregnancy does not significantly increase their risk for disease recurrence in the short term

From San Antonio Breast Cancer Symposium 2022:
The CAPItello-291 trial adds support for use of capivasertib plus fulvestrant for the treatment of advanced breast cancer patients who have progressed after endocrine-based therapy

From the 64th American Society of Hematology Annual Meeting:
Phase I/II trial data point to the promising efficacy and tolerability of the GPRC5D- and CD3-targeted agent talquetamab in heavily pretreated patients with relapsed or refractory multiple myeloma

From ESMO Immuno-Oncology Congress 2022:
A monoclonal antibody treatment given with GM-CSF has achieved objective responses and durable survival outcomes for high-risk refractory or relapsed neuroblastoma and residual bone disease